TD Private Client Wealth’s Agios Pharmaceuticals AGIO Stock Holding History

TD Private Client Wealth’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11	Closed	-$508	–	1163
2021 Q3	$508	Hold	11	–	–	﹤0.01%	1166
2021 Q2	$606	Hold	11	–	–	﹤0.01%	1160
2021 Q1	$568	Hold	11	–	–	﹤0.01%	1115
2020 Q4	$477	Hold	11	–	–	﹤0.01%	1087
2020 Q3	$385	Hold	11	–	–	﹤0.01%	1056
2020 Q2	$588	Hold	11	–	–	﹤0.01%	1009
2020 Q1	$390	Hold	11	–	–	﹤0.01%	987
2019 Q4	$525	Buy	+11	New	+$416	﹤0.01%	988

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

TD Private Client Wealth's AGIO Position: Q4 2021 in Review

TD Private Client Wealth sold out of Agios Pharmaceuticals (AGIO) in Q4 2021, closing a stake of 11 shares — an estimated $508 sold.

TD Private Client Wealth first reported a position in AGIO in Q4 2019 and held it in 8 quarters. The position peaked at $606 in Q2 2021. 160 funds tracked by Wall St. Rank hold AGIO as of Q4 2021.

TD Private Client Wealth reported no remaining Agios Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
TD Private Client Wealth sold 11 Agios Pharmaceuticals shares in Q4 2021, an estimated $508.
TD Private Client Wealth first reported a position in Agios Pharmaceuticals in Q4 2019 and held it in 8 quarters.
TD Private Client Wealth's Agios Pharmaceuticals position peaked at $606 in Q2 2021.
160 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2021.

Based on TD Private Client Wealth's 13F filing for Q4 2021, filed 16 Aug 2024.